| Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study P Andell, X Li, A Martinsson, C Andersson, M Stagmo, B Zöller, ... Heart 103 (21), 1696-1703, 2017 | 265 | 2017 |
| Anemia in the general population: prevalence, clinical correlates and prognostic impact A Martinsson, C Andersson, P Andell, S Koul, G Engström, JG Smith European journal of epidemiology 29, 489-498, 2014 | 101 | 2014 |
| Delay from first medical contact to primary PCI and all‐cause mortality: a nationwide study of patients with ST‐elevation myocardial infarction S Koul, P Andell, A Martinsson, J Gustav Smith, J van der Pals, ... Journal of the American Heart Association 3 (2), e000486, 2014 | 97 | 2014 |
| Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction P Andell, S Koul, A Martinsson, J Sundström, T Jernberg, JG Smith, ... Open heart 1 (1), e000002, 2014 | 97 | 2014 |
| Intravascular ultrasound guidance is associated with better outcome in patients undergoing unprotected left main coronary artery stenting compared with angiography guidance alone P Andell, S Karlsson, MA Mohammad, M Götberg, S James, J Jensen, ... Circulation: Cardiovascular Interventions 10 (5), e004813, 2017 | 85 | 2017 |
| Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries N Danchin, M Lettino, U Zeymer, P Widimsky, A Bardaji, JA Barrabes, ... European Heart Journal-Cardiovascular Pharmacotherapy 2 (3), 152-167, 2016 | 71 | 2016 |
| β‐Blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study P Andell, D Erlinge, JG Smith, J Sundström, B Lindahl, S James, S Koul Journal of the American Heart Association 4 (4), e001611, 2015 | 67 | 2015 |
| P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries U Zeymer, P Widimsky, N Danchin, M Lettino, A Bardaji, JA Barrabes, ... European Heart Journal–Cardiovascular Pharmacotherapy 2 (4), 229-243, 2016 | 65 | 2016 |
| Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in myocardial infarction patients with renal dysfunction M Evans, JJ Carrero, K Szummer, A Åkerblom, R Edfors, J Spaak, ... Journal of the American College of Cardiology 67 (14), 1687-1697, 2016 | 62 | 2016 |
| Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non–ST-segment elevation myocardial infarction K Szummer, J Oldgren, L Lindhagen, JJ Carrero, M Evans, J Spaak, ... Jama 313 (7), 707-716, 2015 | 58 | 2015 |
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes and chronic obstructive pulmonary disease: an analysis from the Platelet Inhibition and Patient Outcomes … P Andell, SK James, CP Cannon, DD Cyr, A Himmelmann, S Husted, ... Journal of the American Heart Association 4 (10), e002490, 2015 | 56 | 2015 |
| Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes M Lettino, P Andell, U Zeymer, P Widimsky, N Danchin, A Bardaji, ... European Heart Journal–Cardiovascular Pharmacotherapy 3 (4), 198-213, 2017 | 53 | 2017 |
| Culprit vessel: impact on short-term and long-term prognosis in patients with ST-elevation myocardial infarction A Entezarjou, MA Mohammad, P Andell, S Koul Open Heart 5 (2), e000852, 2018 | 38 | 2018 |
| Familial aggregation of aortic valvular stenosis: a nationwide study of sibling risk A Martinsson, X Li, B Zöller, P Andell, C Andersson, K Sundquist, ... Circulation: Cardiovascular Genetics 10 (6), e001742, 2017 | 32 | 2017 |
| Intracoronary near-infrared spectroscopy and the risk of future cardiovascular events S Karlsson, E Anesäter, K Fransson, P Andell, J Persson, D Erlinge Open heart 6 (1), e000917, 2019 | 31 | 2019 |
| Impact of baseline anemia in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a prespecified analysis from the VALIDATE‐SWEDEHEART trial A Wester, R Attar, MA Mohammad, P Andell, R Hofmann, J Jensen, ... Journal of the American Heart Association 8 (16), e012741, 2019 | 30 | 2019 |
| The effect of schizophrenia on major adverse cardiac events, length of hospital stay, and prevalence of somatic comorbidities following acute coronary syndrome R Attar, JB Valentin, P Freeman, P Andell, J Aagaard, SE Jensen European Heart Journal-Quality of Care and Clinical Outcomes 5 (2), 121-126, 2019 | 28 | 2019 |
| Reclassification of treatment strategy with instantaneous wave-free ratio and fractional flow reserve: a substudy from the iFR-SWEDEHEART trial P Andell, K Berntorp, EH Christiansen, IJ Gudmundsdottir, L Sandhall, ... JACC: Cardiovascular Interventions 11 (20), 2084-2094, 2018 | 26 | 2018 |
| Peripheral artery disease and outcomes in patients with acute myocardial infarction R Attar, A Wester, S Koul, S Eggert, P Andell Open Heart 6 (1), e001004, 2019 | 25 | 2019 |
| Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with … MA Mohammad, P Andell, S Koul, S James, F Scherstén, M Götberg, ... Platelets 28 (4), 414-416, 2017 | 24 | 2017 |
